Bubendorf, Switzerland, Tuesday, December 8, 2020 - CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested [...]
Bubendorf, Switzerland, Thursday, October 15, 2020 - CIS Pharma’s drug carrier technology has reached invitro proof of concept. A model antibody (Trastuzumab) was conjugated to two polymer carriers that were [...]
Bubendorf, Switzerland, Thursday, May 14, 2020 - CIS Pharma’s polymer expert team has successfully reached the next milestone in its synthesis of the lead polymer carrier. Both analytical protocols as [...]
Milano, Italy, Monday February 3 to Wednesday February 5, 2020 - CIS Pharma attends the sarcoma symposium of the European Society for Medical Oncology, EMSO, in Milano. The event is [...]
Bubendorf, Switzerland, Wednesday, January 8, 2020 - In several laoding experiments Lutetium-177 and Indium-111 were loaded to CIS Pharma’s polymer-drug carriers, at high efficiency reates. Labeling density was close the [...]
Bubendorf, Switzerland, Monday, December 9, 2019 - CIS Pharm has tested several of its new polymer-drug carriers to conjugate radionuclides in a multiparameter cytotoxicity study at Cyprotex, a CRO based [...]
Bubendorf, Switzerland, Friday, November 1, 2019 - Within the scope of the proof-of-concept study at the Paul Scherer Institute, a number of polymer-drug carriers enabling the conjugation of different amounts [...]
New York, USA, Monday, October 28, 2019 - Actinium Pharmaceuticals Inc. announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, an antibody-radionuclide conjugate, including feasibility and [...]
Bubendorf, Switzerland, Wednesday, September 5, 2019 - CIS Pharma has signed a research agreement with the Paul Scherer Institute, Switzerland. The program comprises an invitro and invivo program for the [...]
Maryland, USA, Monday, June 10, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Polivy - polatuzumab vedotin-piiq, Roche - in combination with the chemotherapy bendamustine and [...]